Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview Globe Newswire - Tue Aug 9, 2022

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents...

TARA : 2.76 (-7.69%)
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting Globe Newswire - Thu May 26, 2022

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 2.76 (-7.69%)
Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview Globe Newswire - Thu May 5, 2022

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash...

TARA : 2.76 (-7.69%)
Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? Zacks - Mon Apr 11, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable,...

TARA : 2.76 (-7.69%)
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer Globe Newswire - Thu Mar 24, 2022

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 2.76 (-7.69%)
Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? Zacks - Wed Mar 23, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 687.9% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable,...

TARA : 2.76 (-7.69%)
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview Globe Newswire - Wed Mar 9, 2022

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021...

TARA : 2.76 (-7.69%)
Protara Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire - Wed Mar 2, 2022

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 2.76 (-7.69%)
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer Globe Newswire - Mon Jan 10, 2022

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 2.76 (-7.69%)
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference Globe Newswire - Tue Jan 4, 2022

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 2.76 (-7.69%)

Barchart Exclusives

Chart of the Day: FTAI Infrastructure - Money in Industrials Barchart - 17 minutes ago
The Chart of the Day belongs to the industrial conglomerate FTAI Infrastructure (FIP) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot